logo
logo

Alchemab Raises £60M ($82M) In Series A Financing To Advance Novel Platform For Identifying Disease-Modifying Antibody Therapeutics

Apr 15, 2021over 4 years ago

Amount Raised

€60

Round Type

series a

Cambridge

Description

Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round.

Company Information

Company

Alchemab

Location

Cambridge, Maryland, United States

About

Alchemab has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics on the basis of patient B-cell antibody repertoires. The platform uses well-defined patient samples and a range of functional and advanced analytical techniques to evaluate convergent protective antibody responses in groups of individuals that are susceptible but resilient to specific diseases.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech